Tardive Dyskinesia

March 5th 2025

Neurocrine Biosciences has initiated a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-1140675 for certain neurological and neuropsychiatric conditions, such as tardive dyskinesia.

February 27th 2025

Newly shared top-line phase 4 data demonstrates clinically meaningful and sustained effects of Ingrezza capsules on the physical, social, and emotional impacts experienced with tardive dyskinesia.

December 10th 2024

Check out 2 new psychopharmacology innovations!

September 24th 2024

A new analysis from a 3-year open-label extension study revealed that treatment with deutetrabenazine was associated with long term improvement of symptoms of tardive dyskinesia.